| Title : The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients - Balas_2007_J.Clin.Endocrinol.Metab_92_1249 |
| Author(s) : Balas B , Baig MR , Watson C , Dunning BE , Ligueros-Saylan M , Wang Y , He YL , Darland C , Holst JJ , Deacon CF , Cusi K , Mari A , Foley JE , DeFronzo RA |
| Ref : J Clinical Endocrinology Metab , 92 :1249 , 2007 |
| Abstract : Balas_2007_J.Clin.Endocrinol.Metab_92_1249 |
| ESTHER : Balas_2007_J.Clin.Endocrinol.Metab_92_1249 |
| PubMedSearch : Balas_2007_J.Clin.Endocrinol.Metab_92_1249 |
| PubMedID: 17244786 |
Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA (2007)
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients
J Clinical Endocrinology Metab
92 :1249
Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA (2007)
J Clinical Endocrinology Metab
92 :1249